pSivida (PSDV) Enters Evaluation Agreement with Leading Pharma Co. for Durasert(TM)

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/23/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA

6. BABA
7. AVGO
8. SPCX
9. NTES
10. DE

Top News Most Read Special Reports

Wall St rises on the day but falls for the week; bond yields and Iran in focus
UBS says bull market has further to run
S&P 500 may pull back before midterms, but Citi says buy the dip
Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails

November 22, 2011 9:02 AM EST

E-mail

Get Alerts PSDV Hot Sheet

Price: $1.22 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

pSivida (Nasdaq: PSDV) announces a tech evaluation agreement with a leading global pharma company to evaluation pSivida's bioerodible Durasert(TM) drug delivery technology in opthalmology.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

Create E-mail Alert Related Categories

Corporate News, FDA

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

pSivida (PSDV) Enters Evaluation Agreement with Leading Pharma Co. for Durasert(TM)

Get Alerts PSDV Hot Sheet

Join SI Premium – FREE

You May Also Be Interested In

Create E-mail Alert Related Categories

Sign up for StreetInsider Free!

Free News Feed